Women, harm reduction and HIV

被引:85
作者
Pinkham, Sophie [1 ]
Malinowska-Sempruch, Kasia [2 ]
机构
[1] Open Soc Inst, Int Harm Reduct Dev Program, New York, NY USA
[2] Open Soc Inst, Global Drug Policy Program, Warsaw, Poland
关键词
injection drug use; HIV; gender; sexual and reproductive health; Eastern Europe region; Asia region; United States;
D O I
10.1016/S0968-8080(08)31345-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Gender shapes the experience of drug use and its associated risks. In most parts of the world, however, harm reduction and drug treatment programmes that tailor their services to meet women's needs are rare or nonexistent. Many existing services inadvertently exclude women, and discriminatory policies and social stigma drive women drug users from care and expose them to human rights abuses. Women drug users often provide sex in exchange for housing, sustenance and protection, suffer violence from sexual partners and practise unsafe sex. This paper, drawing upon evidence from existing studies, examines ways in which gender-related factors can increase women drug users' vulnerability and decrease their access to harm reduction, drug treatment and sexual and reproductive health services. It recommends designing services with low-threshold access for women drug users that help them to become more independent, involving the women in designing services and policies, making programmes available for mothers, incorporating sexual and reproductive health into harm reduction services, providing gender-sensitive drug treatment and integrated harm reduction programmes for drug-using sex workers, connecting with domestic violence and rape prevention services and educating mainstream providers. Overall, investigating the circumstances women drug users face will help to formulate policies and programmes that better serve women who use drugs. (C) 2008 Open Society Institute. All rights reserved.
引用
收藏
页码:168 / 181
页数:14
相关论文
共 85 条
[31]   SEX-DIFFERENCES IN PATTERNS OF DRUG TAKING BEHAVIOR - A STUDY AT A LONDON COMMUNITY DRUG TEAM [J].
GOSSOP, M ;
GRIFFITHS, P ;
STRANG, J .
BRITISH JOURNAL OF PSYCHIATRY, 1994, 164 :101-104
[32]   HIV in central and eastern Europe [J].
Hamers, FF ;
Downs, AM .
LANCET, 2003, 361 (9362) :1035-1044
[33]  
JENKINS C, 2002, M HIV PREV DRUG US P
[34]   HIV among transgendered people [J].
Kenagy, GP .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2002, 14 (01) :127-134
[35]  
Klee H., 2002, Drug misuse and motherhood
[36]   HIV risk profile of drug-using women who have sex with women in 19 United States cities [J].
Kral, AH ;
Lorvick, J ;
Bluthenthal, RN ;
Watters, JK .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 16 (03) :211-217
[37]   Risk factors among IDUs who give injections to or receive injections from other drug users [J].
Kral, AH ;
Bluthenthal, RN ;
Erringer, EA ;
Lorvick, J ;
Edlin, BR .
ADDICTION, 1999, 94 (05) :675-683
[38]   Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis [J].
Kral, AH ;
Bluthenthal, RN ;
Lorvick, J ;
Gee, L ;
Bacchetti, P ;
Edlin, BR .
LANCET, 2001, 357 (9266) :1397-1401
[39]   Buprenorphine in pregnant opioid-dependent women: first results of a prospective study [J].
Lacroix, I ;
Berrebi, A ;
Chaumerliac, C ;
Lepeyre-Mestre, M ;
Montastruc, JL ;
Damase-Michel, C .
ADDICTION, 2004, 99 (02) :209-214
[40]   People and places: Behavioral settings and personal network characteristics as correlates of needle sharing [J].
Latkin, C ;
Mandell, W ;
Vlahov, D ;
Oziemkowska, M ;
Celentano, D .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 13 (03) :273-280